The funds will be used to progress the company’s two lead oral live bacterial therapeutics (LBTs), MB097 and MB310, to Phase Ib clinical studies
Microbiotica, a developer of microbiome-based therapeutics and biomarkers, today announced the completion of a £50m ($67m) Series B financing round, co-led by Flerie Invest and Tencent.
Investors also included British Patient Capital, Cambridge Innovation Capital, IP Group, and Seventure Partners.
The funds will be used to progress the company’s two lead oral live bacterial therapeutics (LBTs), MB097 and MB310, to Phase Ib clinical studies.
Both LBTs are precision medicines derived by clinical microbiome profiling using the company’s technology platform, which links consortia of bacteria with clinical trial outcome data. Both products have also been validated and mechanistically characterised pre-clinically through in vivo efficacy data and ex vivo human cell data, the company says.
Funds will also be used to expand the company’s discovery pipeline of biomarkers and LBTs in additional disease areas.
Mike Romanos, co-founder and CEO of Microbiotica, said: “This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome’s therapeutic potential and Microbiotica’s unique capabilities.
“With this additional investment, we will be able to conduct clinical trials with our lead products in immuno-oncology and ulcerative colitis. We will also expand our portfolio of microbiome-based products which have the potential to benefit patients globally.”
Carl-Johan Spak, Senior Advisor at Flerie Invest, commented: “There is ever increasing evidence that the microbiome plays an important role in human health and in multiple diseases, providing completely new therapeutic opportunities in biomedicine. We believe that Microbiotica’s world-leading platform, comprising their unique microbial genomes database, advanced microbiology and bioinformatics will lead to breakthrough results and transformational medicines in the microbiome field.”